SEC Filings
Maze Therapeutics' Loss Widens To $48 Million As Its Experimental Drug Programs Cost More
Maze expects its $477 million cash and investment balance to fund operations into 2029, with kidney drug results due in early 2027.
Maze Therapeutics (MAZE) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
Maze expects its $477 million cash and investment balance to fund operations into 2029, with kidney drug results due in early 2027.
SEC Filings
The exchange leaves Maze with 53,931,889 common shares outstanding, according to its 8-K.